viracta.com - VIRX Operating profit EBITDA
Viracta Therapeutics management is focused on creating innovative methods to combat viral tumors. The actual size of operating profit demonstrates current business efficiency, where serves as the current parameter value. The company minimizes its environmental footprint during drug development, while exclusive patent rights for lymphoma therapy provide it with a significant competitive advantage.
Viracta Therapeutics, Inc. (VIRX) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Viracta Therapeutics|VIRX - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Viracta Therapeutics Inc.|VIRX - Company Debts|Debt to Net Assets Ratio Viracta Therapeutics|VIRX - Company Long-Term Debts|Company Short-Term Debts Viracta Therapeutics|Quick Liquidity Indicator viracta.com
- earnings and market ratios statistics:
VIRX - Net Income|Future Net Profit Viracta Therapeutics|VIRX - P/E Multiple|Forward P/E Multiple Viracta Therapeutics Inc.|VIRX - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Viracta Therapeutics|VIRX - Operating profit before deduction of amortization|Earnings per share for the last four quarters Viracta Therapeutics|VIRX - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months viracta.com|VIRX - Earnings growth in current year|Expected net earnings per share growth next year Viracta Therapeutics
Analysis of all company metrics:Viracta Therapeutics
This indicator measures net cash flow from operating activities before depreciation and amortization, allowing for an assessment of the business's actual ability to generate profit regardless of debt load. An analysis of the EBITDA value for Viracta Therapeutics (VIRX) confirms the effectiveness of ESG standard integration and the minimization of bio-waste in biopharmaceuticals, protecting the investor from overpaying for overvalued assets through precise tracking of operating return expansion rates.
Who Viracta Therapeutics competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Operating profit before deduction of amortization PSNL (Personalis, Inc.)|Profit before payment of interest, taxes and amortization ERAS (erasca.com)|Operating profit EBITDA DCTH (Delcath Systems)|Operating income before deduction of amortization Y-mAbs Therapeutics Inc (YMAB)|AURA - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization CADL (Candel Therapeutics)|ARAY: Operating profit EBITDA|SELLAS Life Sciences Group (SLS) - Operating profit EBITDA|ACTU (Actuate Therapeutics) - Operating profit EBITDA|Operating profit before deduction of amortization Citius Oncology Inc. (CTOR)|Operating profit before deduction of amortization HURA (TuHURA Biosciences, Inc.)|Company profit before taxes, interest and amortization TARA|Operating profit EBITDA FATE (Fate Therapeutics, Inc.)|Operating profit EBITDA Aadi Bioscience, Inc. WHWK|TCRX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization CSBR (Champions Oncology)|XBIT (xbiotech.com) - Operating profit before deduction of amortization|CVM: Company profit before taxes, interest and amortization|OSTX (OS Therapies Incorporated) - Operating profit EBITDA|RADX: Income before deduction of interest, taxes and amortization|Operating profit EBITDA ARTV|ANL - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Veru Pharma VERU|Income before deduction of interest, taxes and amortization TPST|Xilio - Operating profit EBITDA|RENB - Operating profit EBITDA|muraloncology.com (MURA) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization KAPA (Kairos Pharma)|OKUR (OnKure Therapeutics, Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization CytoMed GDTC|Operating profit before deduction of amortization CRIS (Curis, Inc.)|Operating profit EBITDA apollomicsinc.com (APLM)|Tharimmune - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization ADVB (Advanced Biomed Inc.)|Genprex, Inc - Operating profit EBITDA|Operating income before deduction of amortization Calidi Biotherapeutics CLDI|SBFM: Operating profit EBITDA|Operating profit before deduction of amortization Xenetic Biosciences, Inc.|Profit before payment of interest, taxes and amortization Salarius Pharmaceuticals, Inc.|Purple Biotech Ltd (PPBT) - Operating income before deduction of amortization|Operating profit before deduction of amortization AONC (American Oncology Network)|Profit before payment of interest, taxes and amortization BGNE (BeiGene Ltd)|Operating profit EBITDA CKPT (Checkpoint Therapeutics)|Operating income before deduction of amortization elevationoncology.com (ELEV)|ICAD - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization IKNA (Ikena Oncology, Inc.)|NTBL (Notable Labs Inc.) - Operating profit before deduction of amortization|Operating profit before amortization MOR|NAYA (NAYA Biosciences) - Operating profit EBITDA|Operating profit before deduction of amortization ascentage.com (AAPGV)
